BR112022020497A2 - Combinações antitumor contendo conjugados de anticorpo anti-ceacam5 e folfox - Google Patents
Combinações antitumor contendo conjugados de anticorpo anti-ceacam5 e folfoxInfo
- Publication number
- BR112022020497A2 BR112022020497A2 BR112022020497A BR112022020497A BR112022020497A2 BR 112022020497 A2 BR112022020497 A2 BR 112022020497A2 BR 112022020497 A BR112022020497 A BR 112022020497A BR 112022020497 A BR112022020497 A BR 112022020497A BR 112022020497 A2 BR112022020497 A2 BR 112022020497A2
- Authority
- BR
- Brazil
- Prior art keywords
- folfox
- conjugates
- ceacam5 antibody
- combinations containing
- containing anti
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6853—Carcino-embryonic antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Abstract
COMBINAÇÕES ANTITUMOR CONTENDO CONJUGADOS DE ANTICORPO ANTI-CEACAM5 E FOLFOX. A presente invenção refere-se a conjugados de anticorpo compreendendo um anticorpo anti-CEACAM5 para uso para tratamento de câncer em combinação com ácido folínico, 5-fluor-uracila e oxaliplatina (FOLFOX). A invenção refere-se ainda a composições farmacêuticas e estojos de elementos compreendendo um anticorpo anti-CEACAM5 em combinação com ácido folínico, 5-fluor-uracila e oxaliplatina (FOLFOX) para uso para tratamento de câncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20315218 | 2020-04-24 | ||
PCT/EP2021/060537 WO2021214223A1 (en) | 2020-04-24 | 2021-04-22 | Antitumor combinations containing anti-ceacam5 antibody conjugates and folfox |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022020497A2 true BR112022020497A2 (pt) | 2022-12-06 |
Family
ID=70977892
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022020497A BR112022020497A2 (pt) | 2020-04-24 | 2021-04-22 | Combinações antitumor contendo conjugados de anticorpo anti-ceacam5 e folfox |
Country Status (12)
Country | Link |
---|---|
US (1) | US20230151088A1 (pt) |
EP (1) | EP4138926A1 (pt) |
JP (1) | JP2023522395A (pt) |
KR (1) | KR20230005203A (pt) |
CN (1) | CN115427082A (pt) |
AU (1) | AU2021260823A1 (pt) |
BR (1) | BR112022020497A2 (pt) |
CA (1) | CA3181005A1 (pt) |
IL (1) | IL297311A (pt) |
MX (1) | MX2022013405A (pt) |
TW (1) | TW202206108A (pt) |
WO (1) | WO2021214223A1 (pt) |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
EP0247091B1 (en) | 1985-11-01 | 1993-09-29 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
EP0563475B1 (en) | 1992-03-25 | 2000-05-31 | Immunogen Inc | Cell binding agent conjugates of derivatives of CC-1065 |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
DK0669836T3 (da) | 1992-11-13 | 1996-10-14 | Idec Pharma Corp | Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom |
DE69535243T2 (de) | 1994-07-13 | 2007-05-10 | Chugai Seiyaku K.K. | Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper |
WO1998045322A2 (en) | 1997-04-10 | 1998-10-15 | Royal Netherlands Academy Of Arts And Sciences | Diagnosis method and reagents |
US6333410B1 (en) | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
JP2006526408A (ja) | 2003-04-22 | 2006-11-24 | アイビーシー、ファーマシューティカルズ | 多価タンパク質複合体 |
KR101667944B1 (ko) | 2007-08-29 | 2016-10-20 | 사노피 | 인간화된 항-cxcr5 항체, 이의 유도체 및 이들의 용도 |
EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
DK2922875T3 (en) | 2012-11-20 | 2017-06-06 | Sanofi Sa | ANTI-CEACAM5 ANTIBODIES AND APPLICATIONS THEREOF |
-
2021
- 2021-04-22 AU AU2021260823A patent/AU2021260823A1/en active Pending
- 2021-04-22 MX MX2022013405A patent/MX2022013405A/es unknown
- 2021-04-22 KR KR1020227038406A patent/KR20230005203A/ko unknown
- 2021-04-22 WO PCT/EP2021/060537 patent/WO2021214223A1/en active Application Filing
- 2021-04-22 TW TW110114490A patent/TW202206108A/zh unknown
- 2021-04-22 EP EP21720281.1A patent/EP4138926A1/en active Pending
- 2021-04-22 US US17/917,375 patent/US20230151088A1/en active Pending
- 2021-04-22 IL IL297311A patent/IL297311A/en unknown
- 2021-04-22 JP JP2022564166A patent/JP2023522395A/ja active Pending
- 2021-04-22 BR BR112022020497A patent/BR112022020497A2/pt unknown
- 2021-04-22 CN CN202180029921.9A patent/CN115427082A/zh active Pending
- 2021-04-22 CA CA3181005A patent/CA3181005A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3181005A1 (en) | 2021-10-28 |
WO2021214223A1 (en) | 2021-10-28 |
EP4138926A1 (en) | 2023-03-01 |
TW202206108A (zh) | 2022-02-16 |
IL297311A (en) | 2022-12-01 |
US20230151088A1 (en) | 2023-05-18 |
KR20230005203A (ko) | 2023-01-09 |
CN115427082A (zh) | 2022-12-02 |
AU2021260823A1 (en) | 2023-01-05 |
JP2023522395A (ja) | 2023-05-30 |
MX2022013405A (es) | 2022-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2023000186A2 (es) | Derivados de quinoxalina como fármacos anti-cáncer | |
BR112022020482A2 (pt) | Combinações antitumor contendo conjugados de anticorpo anti-ceacam5 e folfiri | |
CL2018002787A1 (es) | Compuestos de aminopurina sustituida, composiciones de estos y métodos de tratamiento con estos. | |
BRPI0612845A8 (pt) | composto, formulação farmacêutica, métodos para tratar câncer e para sintetizar um composto de fórmula alq-dispasador | |
CO2021009879A2 (es) | Inhibidores aza-heterobicíclicos de mat2a y métodos de uso para tratar el cáncer | |
BR112015032690A8 (pt) | uso de moléculas inibidoras de semaforina-4d em combinação com uma terapia imunomoduladora para inibir crescimento tumoral e metástases | |
CL2015003285A1 (es) | Arilquinazolinas | |
BR112018075166A2 (pt) | derivados de carbonucleosídeo substituídos úteis como agentes anticâncer | |
BR112016000489A8 (pt) | composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos | |
CL2007001624A1 (es) | Uso de un anticuerpo que se une a dll4 para el tratamiento de tumor, cancer o trastorno de proliferacion celular. | |
BR112014011925A2 (pt) | mutações no receptor notch humano e seu uso | |
EA201390694A1 (ru) | Способы лечения рака | |
BR112021009275A2 (pt) | Anticorpo humanizado anti-sirp alfa ou um fragmento de ligação a antígeno do mesmo, composição farmacêutica, molécula de ácido nucleico, e, célula hospedeira. | |
BR112022021910A2 (pt) | Inibidores da proteína bcl-2 | |
BR112022002029A2 (pt) | Uso de sepiapterina e seus metabólitos para tratar exposição à radiação | |
BR112022020497A2 (pt) | Combinações antitumor contendo conjugados de anticorpo anti-ceacam5 e folfox | |
EA201991305A1 (ru) | Производные тирозина и композиции, включающие их | |
CL2020003357A1 (es) | Métodos para tratar el cáncer de pulmón con un antagonista de fijación al eje pd-1, un agente de platino y un inhibidor de la topoisomerasa ii. | |
BR112023015715A2 (pt) | Inibidor de cdk | |
BR112019002560A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método | |
MX2021000558A (es) | Metodos para tratar el cancer de pulmon con un antagonista de fijacion al eje pd-1, un antimetabolito y un agente de platino. | |
BR112022010278A2 (pt) | Terapia combinada que envolve compostos macrocíclicos de diarila | |
BR112022022418A2 (pt) | Anticorpos de alvejamento de clec12a e uso dos mesmos | |
BR112022020592A2 (pt) | Combinações antitumor contendo conjugados de anticorpo anti-ceacam5, trifluridina e tipiracila | |
BR112022020477A2 (pt) | Combinações antitumor contendo conjugados de anticorpo anti-ceacam5 e cetuximabe |